|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.27 AUD | -1.72% |
|
+0.20% | -17.58% |
| 07-01 | Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment | MT |
| 06-15 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| Market Cap | 518M 360M 315M 291M 268M 509M 34.36B 3.47B 1.36B 16.92B 1.35B 1.32B 58.18B | P/E 2026 * |
14.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 184M 161M 148M 137M 260M 17.53B 1.77B 696M 8.63B 690M 675M 29.68B | EV / Sales 2026 * |
2.66x | EV / Sales 2027 * | 2.2x |
| Free-Float |
83.79% | Yield 2026 * |
0.6% | Yield 2027 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -1.72% | ||
| 1 week | +0.20% | ||
| Current month | -0.10% | ||
| 1 month | +17.78% | ||
| 3 months | +12.98% | ||
| 6 months | -18.75% | ||
| Current year | -17.58% |
| 1 week | 10 |  | 10.58 |
| 1 month | 8.8 | | 10.74 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.6 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24-10-02 | Buy | Director | 8,333 | 0.0166% | ||
| 23-11-26 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 23-11-26 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.72% | +0.20% | -1.91% | -41.08% | 366M | |
| -0.51% | +1.57% | +18.72% | -5.52% | 67.96B | |
| -5.16% | -8.63% | +37.37% | +202.27% | 54.4B | |
| -2.10% | +0.89% | -49.30% | -53.47% | 41.74B | |
| +5.28% | +39.50% | +39.50% | +39.50% | 40.63B | |
| -10.83% | -14.41% | +99.15% | -44.54% | 30.38B | |
| +0.12% | -7.85% | +47.16% | -29.27% | 29.37B | |
| -1.53% | -0.13% | +65.92% | +88.58% | 23.68B | |
| +3.88% | +2.16% | +11.78% | +201.51% | 19.15B | |
| -4.75% | +11.27% | +85.63% | +394.76% | 17.68B | |
| Average | -1.73% | -0.22% | +35.40% | +75.27% | 32.53B | |
| Weighted average by Cap. | -1.72% | -1.32% | +32.42% | +63.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 69.18M 60.51M 55.81M 51.55M 97.82M 6.6B 667M 262M 3.25B 260M 254M 11.17B | 105M 73.28M 64.1M 59.12M 54.61M 104M 6.99B 706M 277M 3.44B 275M 269M 11.84B |
| Net income | 35.97M 25.02M 21.88M 20.18M 18.64M 35.37M 2.39B 241M 94.7M 1.18B 93.93M 91.89M 4.04B | 38.2M 26.57M 23.24M 21.44M 19.8M 37.57M 2.53B 256M 101M 1.25B 99.76M 97.59M 4.29B |
| Net Debt | -254M -176M -154M -142M -131M -250M -16.83B -1.7B -668M -8.29B -663M -648M -28.5B | -286M -199M -174M -161M -148M -281M -18.97B -1.92B -753M -9.35B -747M -731M -32.14B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-10 | A$10.27 | -1.72% | 109,586 |
| 26-07-09 | A$10.45 | +1.65% | 177,685 |
| 26-07-08 | A$10.28 | -0.10% | 144,738 |
| 26-07-07 | A$10.29 | +0.78% | 120,441 |
| 26-07-06 | A$10.21 | -0.39% | 66,784 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
